Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health
Introduction and Purpose: T2DM is a metabolic condition with significant global health implications, largely driven by aging populations and the obesity epidemic. Glucagon-like peptide-1 receptor agonists have transformed T2DM treatment by offering benefits that extend beyond blood glucose c...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-12-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56722 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846113504627523584 |
|---|---|
| author | Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła |
| author_facet | Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła |
| author_sort | Michał Mazur |
| collection | DOAJ |
| description |
Introduction and Purpose:
T2DM is a metabolic condition with significant global health implications, largely driven by aging populations and the obesity epidemic. Glucagon-like peptide-1 receptor agonists have transformed T2DM treatment by offering benefits that extend beyond blood glucose control, including weight reduction, cardiovascular protection, and potential effects on related metabolic conditions. This review aims to explore the mechanisms of GLP-1 RAs, their clinical applications, and their evolving role in addressing T2DM and its associated complications.
Materials and Methods:
The review is based on a detailed analysis of peer-reviewed studies from major scientific databases such as PubMed. The selected literature focuses on the mechanisms, clinical benefits, and new developments in GLP-1 RA therapies, including innovations in drug formulations and combination treatments.
Results:
GLP-1 RAs enhance glycemic control by stimulating glucose-dependent insulin secretion and suppressing glucagon release, with a low risk of hypoglycemia. They also facilitate significant weight loss by regulating appetite and slowing gastric emptying. Beyond these core effects, GLP-1 RAs reduce cardiovascular risks, slow the progression of chronic kidney disease, and show promise in managing NAFLD and neuroinflammation. Innovations such as dual and triple agonists and oral GLP-1 RA formulations have further expanded their therapeutic scope, improving patient outcomes and adherence.
Conclusion:
GLP-1 RAs represent a significant advancement in the management of T2DM and related metabolic disorders. By addressing interconnected issues such as glycemic control, weight management, and cardiovascular risk, these therapies play a central role in modern metabolic medicine. Ongoing research should focus on long-term outcomes, safety, and personalized approaches to maximize their full potential and accessibility.
|
| format | Article |
| id | doaj-art-6720a2df9b9c4188b67fbaf06b5e5b3f |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-6720a2df9b9c4188b67fbaf06b5e5b3f2024-12-21T08:21:23ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-12-013610.12775/QS.2024.36.56722Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic HealthMichał Mazurhttps://orcid.org/0009-0007-3840-4325Dorota Waz0https://orcid.org/0009-0004-7484-9231Jakub Szarłowicz1https://orcid.org/0009-0006-8520-9496Zofia Goliszek2https://orcid.org/0009-0005-9881-5754Karolina Łucja Sobek3https://orcid.org/0009-0000-2551-0515Wiktoria Tabin-Barczak4https://orcid.org/0009-0003-8333-8428Aldona Sokołowska5https://orcid.org/0009-0006-8723-2593Klaudia Fikas6https://orcid.org/0009-0008-1976-2941Kamil Chwaliszewski7https://orcid.org/0009-0003-7239-3122Sebastian Samuła8https://orcid.org/0009-0008-8915-4263Medical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandProvincial Clinical Hospital No. 2 named after saint Jadwiga the Queen in Rzeszów, Lwowska 60, 35-301 RzeszówUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandStefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland Introduction and Purpose: T2DM is a metabolic condition with significant global health implications, largely driven by aging populations and the obesity epidemic. Glucagon-like peptide-1 receptor agonists have transformed T2DM treatment by offering benefits that extend beyond blood glucose control, including weight reduction, cardiovascular protection, and potential effects on related metabolic conditions. This review aims to explore the mechanisms of GLP-1 RAs, their clinical applications, and their evolving role in addressing T2DM and its associated complications. Materials and Methods: The review is based on a detailed analysis of peer-reviewed studies from major scientific databases such as PubMed. The selected literature focuses on the mechanisms, clinical benefits, and new developments in GLP-1 RA therapies, including innovations in drug formulations and combination treatments. Results: GLP-1 RAs enhance glycemic control by stimulating glucose-dependent insulin secretion and suppressing glucagon release, with a low risk of hypoglycemia. They also facilitate significant weight loss by regulating appetite and slowing gastric emptying. Beyond these core effects, GLP-1 RAs reduce cardiovascular risks, slow the progression of chronic kidney disease, and show promise in managing NAFLD and neuroinflammation. Innovations such as dual and triple agonists and oral GLP-1 RA formulations have further expanded their therapeutic scope, improving patient outcomes and adherence. Conclusion: GLP-1 RAs represent a significant advancement in the management of T2DM and related metabolic disorders. By addressing interconnected issues such as glycemic control, weight management, and cardiovascular risk, these therapies play a central role in modern metabolic medicine. Ongoing research should focus on long-term outcomes, safety, and personalized approaches to maximize their full potential and accessibility. https://apcz.umk.pl/QS/article/view/56722type 2 diabetes mellitusGLP-1 receptor agonistcardiovascular benefitsweight managementnon-alcoholic fatty liver diseasetirzepatide |
| spellingShingle | Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health Quality in Sport type 2 diabetes mellitus GLP-1 receptor agonist cardiovascular benefits weight management non-alcoholic fatty liver disease tirzepatide |
| title | Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health |
| title_full | Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health |
| title_fullStr | Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health |
| title_full_unstemmed | Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health |
| title_short | Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health |
| title_sort | beyond glycemic control the expanding role of glp 1 analogues in type 2 diabetes and metabolic health |
| topic | type 2 diabetes mellitus GLP-1 receptor agonist cardiovascular benefits weight management non-alcoholic fatty liver disease tirzepatide |
| url | https://apcz.umk.pl/QS/article/view/56722 |
| work_keys_str_mv | AT michałmazur beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT dorotawaz beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT jakubszarłowicz beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT zofiagoliszek beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT karolinałucjasobek beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT wiktoriatabinbarczak beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT aldonasokołowska beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT klaudiafikas beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT kamilchwaliszewski beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth AT sebastiansamuła beyondglycemiccontroltheexpandingroleofglp1analoguesintype2diabetesandmetabolichealth |